Aditxt (ADTX) to Announce Quarterly Earnings on Wednesday

Aditxt (NASDAQ:ADTX) is projected to issue its results before the market opens on Wednesday, September 2nd. Analysts expect the company to post earnings of ($224,553,600,000.00) per share and revenue of $1.00 million for the quarter.

Aditxt Trading Up 11.8%

ADTX opened at $0.01 on Tuesday. Aditxt has a 1-year low of $0.00 and a 1-year high of $27,092.88. The firm has a market capitalization of $6,201.60, a P/E ratio of -0.00 and a beta of 0.95.

Insider Buying and Selling at Aditxt

In related news, major shareholder Financial Lp Hrt sold 3,132,480 shares of Aditxt stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $0.01, for a total transaction of $31,324.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 3,259,267 shares of company stock worth $32,593 in the last 90 days. 0.01% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ADTX has been the topic of several research analyst reports. Wall Street Zen raised shares of Aditxt to a “sell” rating in a research report on Saturday, May 23rd. Weiss Ratings downgraded shares of Aditxt from a “sell (e+)” rating to a “sell (e)” rating in a report on Wednesday, June 24th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has an average rating of “Sell”.

Aditxt Company Profile

Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.

The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.